TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity

被引:0
|
作者
Yimeng Ren
Yun Qian
Luoyan Ai
Yile Xie
Yaqi Gao
Ziyan Zhuang
Jinxian Chen
Ying-Xuan Chen
Jing-Yuan Fang
机构
[1] Renji Hospital,State Key Laboratory for Oncogenes and Related Genes; Division of Gastroenterology and Hepatology
[2] School of Medicine,Department of Medical Oncology
[3] Shanghai Jiao Tong University,Division of Gastrointestinal Surgery
[4] Zhongshan Hospital,undefined
[5] Fudan University,undefined
[6] Renji Hospital,undefined
[7] School of Medicine,undefined
[8] Shanghai Jiao Tong University,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Tumor cells evade T cell-mediated immunosurveillance via the interaction between programmed death-1 (PD-1) ligand 1 (PD-L1) on tumor cells and PD-1 on T cells. Strategies disrupting PD-1/PD-L1 have shown clinical benefits in various cancers. However, the limited response rate prompts us to investigate the molecular regulation of PD-L1. Here, we identify trafficking protein particle complex subunit 4 (TRAPPC4), a major player in vesicular trafficking, as a crucial PD-L1 regulator. TRAPPC4 interacts with PD-L1 in recycling endosomes, acting as a scaffold between PD-L1 and RAB11, and promoting RAB11-mediated recycling of PD-L1, thus replenishing its distribution on the tumor cell surface. TRAPPC4 depletion leads to a significant reduction of PD-L1 expression in vivo and in vitro. This reduction in PD-L1 facilitates T cell-mediated cytotoxicity. Overexpression of Trappc4 sensitizes tumor cells to checkpoint therapy in murine tumor models, suggesting TRAPPC4 as a therapeutic target to enhance anti-tumor immunity.
引用
收藏
相关论文
共 50 条
  • [21] PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival
    Micevic, Goran
    Thakral, Durga
    McGeary, Meaghan
    Bosenberg, Marcus W.
    PIGMENT CELL & MELANOMA RESEARCH, 2019, 32 (03) : 435 - 440
  • [22] Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
    Kotanides, Helen
    Li, Yiwen
    Malabunga, Maria
    Carpenito, Carmine
    Eastman, Scott W.
    Shen, Yang
    Wang, George
    Inigo, Ivan
    Surguladze, David
    Pennello, Anthony L.
    Persaud, Krishnadatt
    Hindi, Sagit
    Topper, Michael
    Chen, Xinlei
    Zhang, Yiwei
    Bulaon, Danielle K.
    Bailey, Tim
    Lao, Yanbin
    Han, Bing
    Torgerson, Stacy
    Chin, Darin
    Sonyi, Andreas
    Haidar, Jaafar N.
    Novosiadly, Ruslan D.
    Moxham, Christopher M.
    Plowman, Gregory D.
    Ludwig, Dale L.
    Kalos, Michael
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (10) : 1300 - 1310
  • [23] Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1
    Yang, Zhen
    Liu, Xinpeng
    Zhu, Jun
    Chai, Yangyang
    Cong, Boyi
    Li, Bo
    Gao, Wanfeng
    Hu, Ye
    Wen, Mingyue
    Liu, Yanfang
    Fu, Li
    Cao, Xuetao
    CANCER CELL, 2025, 43 (01) : 86 - +
  • [24] IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
    Shao, Lulu
    Hou, Weizhou
    Scharping, Nicole E.
    Vendetti, Frank P.
    Srivastava, Rashmi
    Roy, Chandra Nath
    Menk, Ashley V.
    Wang, Yiyang
    Chauvin, Joe-Marc
    Karukonda, Pooja
    Thorne, Stephen H.
    Hornung, Veit
    Zarour, Hassane M.
    Bakkenist, Christopher J.
    Delgoffe, Greg M.
    Sarkar, Saumendra N.
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (08) : 1258 - 1266
  • [25] Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity
    Yang, Suah
    Shim, Man Kyu
    Song, Sukyung
    Cho, Hanhee
    Choi, Jiwoong
    Jeon, Seong Ik
    Kim, Woo Jun
    Um, Wooram
    Park, Jae Hyung
    Yoon, Hong Yeol
    Kim, Kwangmeyung
    BIOMATERIALS, 2022, 290
  • [26] Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity
    Zhang, Yuankun
    Song, Qingxiao
    Cassady, Kaniel
    Lee, Michael
    Tang, Haidong
    Zheng, Moqian
    Wang, Bixin
    Schones, Dustin E.
    Fu, Yang-Xin
    Riggs, Arthur D.
    Martin, Paul J.
    Feng, Ru
    Zeng, Defu
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (16)
  • [27] Regorafenib attenuates IFN-γ-induced PD-L1 expression and enhances antitumor immunity
    Zhu, Xiao-Feng
    CANCER RESEARCH, 2018, 78 (13)
  • [28] Niraparib enhances antitumor immunity and contributes to the efficacy of PD-L1 blockade in cervical cancer
    Chang, Jie
    Quan, Shimin
    Tian, Sijuan
    Wang, Shirui
    Li, Simin
    Guo, Yanping
    Yang, Ting
    Yang, Xiaofeng
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (06)
  • [29] Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease
    Kemeny, Hanna R.
    Elsamadicy, Aladine A.
    Farber, S. Harrison
    Champion, Cosette D.
    Lorrey, Selena J.
    Chongsathidkiet, Pakawat
    Woroniecka, Karolina, I
    Cui, Xiuyu
    Shen, Steven H.
    Rhodin, Kristen E.
    Tsvankin, Vadim
    Everitt, Jeffrey
    Sanchez-Perez, Luis
    Healy, Patrick
    McLendon, Roger E.
    Codd, Patrick J.
    Dunn, Ian F.
    Fecci, Peter E.
    CLINICAL CANCER RESEARCH, 2020, 26 (05) : 1141 - 1151
  • [30] Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade
    Mitsuhashi, Atsushi
    Koyama, Kazuya
    Ogino, Hirokazu
    Afroj, Tania
    Nguyen, Na Thi
    Yoneda, Hiroto
    Otsuka, Kenji
    Sugimoto, Masamichi
    Kondoh, Osamu
    Nokihara, Hiroshi
    Hanibuchi, Masak
    Takizawa, Hiromitsu
    Shinohara, Tsutomu
    Nishioka, Yasuhiko
    CELL REPORTS, 2023, 42 (03):